Samsung wins first CHMP backing for a Herceptin biosim, imperiling $2B in Roche sales

15th September 2017 Uncategorised 0

As challengers to Roche’s cancer blockbusters advance in the U.S. and around the world, Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe. A drug panel there recommended the proposed biosim, Ontruzant, creating a potential near-term threat to billions of Roche sales on the continent.

More: Samsung wins first CHMP backing for a Herceptin biosim, imperiling B in Roche sales
Source: fierce